Although pharmacological therapy with transthyretin stabilizers, such as tafamidis, has been shown to reduce mortality in patients with ATTRwt cardiac amyloidosis (ATTRwt-CA), the role of device-based therapies, such as cardiac resynchronization therapy (CRT), remains controversial, particularly in patients with coexisting conduction abnormalities. Here, TTR is linked to cardiac amyloidosis.